An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
Study Identifier
M19-388
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
2022-501522-38-00
For general inquiries, please contact
Recruitment Complete
Study Details
Medical Condition
Study Drug
Phase
Phase 3
Sex
Female & Male
Age
N/A
Protocol Summary
The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.
Study Locations
Location
Status
Location
University of Arizona Cancer Center - Tucson /ID# 210548
Tucson, Arizona, United States, 85724
Status
Not applicable
Location
UCLA Santa Monica Hematology Oncology /ID# 210551
Los Angeles, California, United States, 90095
Status
Not applicable
Location
Ingalls Memorial Hosp /ID# 210553
Harvey, Illinois, United States, 60426
Status
Not applicable
Location
Dana-Farber Cancer Institute /ID# 215360
Boston, Massachusetts, United States, 02215
Status
Not applicable
Location
University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 231132
Ann Arbor, Michigan, United States, 48109
Status
Not applicable
Location
Dartmouth-Hitchcock Medical Center /ID# 210555
Lebanon, New Hampshire, United States, 03756
Status
Not applicable
Showing {first} - {last} of {total} Results